Title: Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Aug 6

PMID 32752023

Citations 6

Authors

Yoshiko Fukuda

Yoichi Sakurada

Atsushi Sugiyama

Seigo Yoneyama

Mio Matsubara

Wataru Kikushima

Naohiko Tanabe

Ravi Parikh

Kenji Kashiwagi

Affiliations

Soon will be listed here.

Abstract

We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all -value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year.

Citing Articles

Comparative Efficacy of Brolucizumab and Aflibercept in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis.

Allehyani M, Alsaeedi A, Alqthmi R, Saleh R, Alsamli R, Almalki H Cureus. 2025; 17(1):e77073.

PMID: 39917144 PMC: 11801107. DOI: 10.7759/cureus.77073.

Clinical Characteristics of Punctate Hyperfluorescence Spots in the Fellow Eye of Patients with Unilateral Macular Neovascularization with No Drusen.

Kamao H, Goto K, Date Y, Hiraki R, Mizukawa K, Miki A J Clin Med. 2024; 13(18).

PMID: 39336881 PMC: 11432401. DOI: 10.3390/jcm13185394.

Clinical Characteristics of Unilateral Macular Neovascularization Patients with Pachydrusen in the Fellow Eye.

Kamao H, Mitsui E, Date Y, Goto K, Mizukawa K, Miki A J Clin Med. 2024; 13(13).

PMID: 38999321 PMC: 11242765. DOI: 10.3390/jcm13133757.

Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.

Kimura M, Sakurada Y, Fukuda Y, Matsubara M, Kotoda Y, Kasai Y Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931354 PMC: 11206239. DOI: 10.3390/ph17060687.

Association of Fundus Autofluorescence Abnormalities and Pachydrusen in Central Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy.

Lai T, Tang Z, Lai A, Szeto S, Lai R, Cheung C J Clin Med. 2022; 11(18).

PMID: 36142987 PMC: 9500611. DOI: 10.3390/jcm11185340.

References

Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C . Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308(5720):385-9. PMC: 1512523. DOI: 10.1126/science.1109557. View

Yamamoto A, Okada A, Kano M, Koizumi H, Saito M, Maruko I . One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Ophthalmology. 2015; 122(9):1866-72. DOI: 10.1016/j.ophtha.2015.05.024. View

Rivera A, Fisher S, Fritsche L, N Keilhauer C, Lichtner P, Meitinger T . Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005; 14(21):3227-36. DOI: 10.1093/hmg/ddi353. View

Cheng C, Yamashiro K, Chen L, Ahn J, Huang L, Huang L . New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun. 2015; 6:6063. PMC: 4317498. DOI: 10.1038/ncomms7063. View

Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A . Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. Sci Rep. 2017; 7:44020. PMC: 5339812. DOI: 10.1038/srep44020. View

Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tateno Y, Tanabe N . Role of complement factor H I62V and age-related maculopathy susceptibility 2 A69S variants in the clinical expression of polypoidal choroidal vasculopathy. Ophthalmology. 2011; 118(7):1402-7. DOI: 10.1016/j.ophtha.2010.12.010. View

Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kikushima W, Mabuchi F . Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration. PLoS One. 2016; 11(2):e0149978. PMC: 4769020. DOI: 10.1371/journal.pone.0149978. View

Spaide R . DISEASE EXPRESSION IN NONEXUDATIVE AGE-RELATED MACULAR DEGENERATION VARIES WITH CHOROIDAL THICKNESS. Retina. 2017; 38(4):708-716. DOI: 10.1097/IAE.0000000000001689. View

Khan K, Mahroo O, Khan R, Mohamed M, McKibbin M, Bird A . Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res. 2016; 53:70-106. DOI: 10.1016/j.preteyeres.2016.04.008. View

10.

Sakurada Y, Parikh R, Gal-Or O, Balaratnasingam C, Leong B, Tanaka K . CUTICULAR DRUSEN: Risk of Geographic Atrophy and Macular Neovascularization. Retina. 2020; 40(2):257-265. DOI: 10.1097/IAE.0000000000002399. View

11.

Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A . Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. Ophthalmology. 2015; 122(11):2303-10. DOI: 10.1016/j.ophtha.2015.06.053. View

12.

Fukuda Y, Sakurada Y, Yoneyama S, Kikushima W, Sugiyama A, Matsubara M . Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration. Sci Rep. 2019; 9(1):11906. PMC: 6695414. DOI: 10.1038/s41598-019-48494-6. View

13.

Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H . Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2016; 255(2):311-316. DOI: 10.1007/s00417-016-3467-y. View

14.

Hayashi H, Yamashiro K, Gotoh N, Nakanishi H, Nakata I, Tsujikawa A . CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2010; 51(11):5914-9. DOI: 10.1167/iovs.10-5554. View

15.

Morimoto M, Matsumoto H, Mimura K, Akiyama H . Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017; 255(10):1891-1897. DOI: 10.1007/s00417-017-3718-6. View

16.

Sakurada Y, Kubota T, Mabuchi F, Imasawa M, Tanabe N, Iijima H . Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2008; 145(6):1058-1062. DOI: 10.1016/j.ajo.2008.02.007. View

17.

Wataru K, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, Parikh R . Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS One. 2020; 15(2):e0229231. PMC: 7039440. DOI: 10.1371/journal.pone.0229231. View

18.

Sakurada Y, Sugiyama A, Kikushima W, Yoneyama S, Tanabe N, Matsubara M . Pseudodrusen pattern and development of late age-related macular degeneration in the fellow eye of the unilateral case. Jpn J Ophthalmol. 2019; 63(5):374-381. DOI: 10.1007/s10384-019-00680-9. View

19.

Ferris F, Davis M, Clemons T, Lee L, Chew E, Lindblad A . A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005; 123(11):1570-4. PMC: 1473206. DOI: 10.1001/archopht.123.11.1570. View

20.

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi M, Shi E . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2):171-85. PMC: 3338918. DOI: 10.1007/s10456-011-9249-6. View